Published in In Vivo, November 2021
Authors: Dr. Nicholas Frame and Dr. Oded Ben-Joseph
The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read the full article from Life Science Magazine here: Read MoreRead More
Outcome Capital Life Science Market Pulse January 2024 Click to view our LifeSciences Pulse NewsletterDownload